Oncolytics Biotech Inc. filed a Form 8-K on November 4, 2026, announcing the release of translational data from its study in squamous cell anal cancer patients, focusing on pelareorep's ability to impact the immune system in HPV-driven tumors.

Key Highlights

  • Study focus: The press release addressed translational data from a study in squamous cell anal cancer patients, according to the filing.
  • Drug highlighted: The data concerned pelareorep and its ability to impact the immune system in HPV-driven tumors, as disclosed in the filing.
  • Event date: The press release was issued on November 4, 2026, the same date as the filing.
  • Filing classification: The information in Item 8.01 and Exhibit 99.1 is furnished and "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934," per the filing's own language.
  • Signatory: The report was signed by Kirk Look, Chief Financial Officer of Oncolytics Biotech Inc.

Pelareorep Translational Data in Squamous Cell Anal Cancer

Oncolytics Biotech Inc. (NASDAQ:ONCY) filed a current report on November 4, 2026, disclosing that the company issued a press release on the same date. According to the filing, the press release announced translational data from a study in squamous cell anal cancer patients, specifically examining pelareorep's ability to impact the immune system in HPV-driven tumors. The filing did not include the underlying data itself; that information was attached as Exhibit 99.1.

The filing was made under Item 8.01 (Other Events). The company stated that the information set forth in Item 8.01 and in Exhibit 99.1 "is furnished and shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section." No financial figures, clinical trial endpoints, or patient outcome data were included in the body of the 8-K itself.

The report was signed on behalf of Oncolytics Biotech Inc. by Kirk Look, identified in the filing as Chief Financial Officer. The company is incorporated in Nevada and lists its principal executive offices at 4350 Executive Drive, Suite 325, San Diego, CA 92121.

What Was Disclosed

Oncolytics Biotech filed an 8-K on November 4, 2026, announcing translational data from a pelareorep study in squamous cell anal cancer patients related to immune system effects in HPV-driven tumors. The data itself was contained in the attached press release, Exhibit 99.1.